KemPharm Shares Trade Higher After FDA Approval For Azstarys In ADHD

by Vandana Singh, Benzinga Editor

March 3, 2021 5:05 AM | 1 min read | Make a Comment

The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.
ADHD is a neurobehavioral disorder of childhood that makes it difficult for a person to pay attention and control impulsive behaviors.
AZSTARYS consists of serdexmethylphenidate, KemPharm's prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
Azstarys will be commercially available in the U.S. as early as the second half of 2021.
Price Action: KMPH shares soared 78.7% at $16.85 in premarket trading on the last check Wednesday.

Posted In: Biotech News Health Care FDA General ADHD

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.